To the editor {#S1}
=============

One approach to improve risk prognostication in patients with Multiple Myeloma (MM) is to use new technologies to stratify patients based on distinct outcomes^[@R1]^. Outcome prediction for most patients is based on the International Staging System (ISS) and the presence or absence of specific fluorescent in-situ hybridization (FISH) abnormalities. Additional biomarkers are necessary to improve precision, and there is evidence that small non-coding RNAs, microRNAs (miRNAs), are involved in MM pathogenesis^[@R2]--[@R4]^, but the predictive role of circulating miRNAs remains to be fully evaluated. To address this question, we measured serum miRNA levels of a large cohort of newly diagnosed MM patients that were uniformly treated and followed, correlating miRNA levels with clinical outcome to test their prognostic impact in a multivariate model.

Patients with previously untreated transplant ineligible MM enrolled on a Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) phase III clinical trial and with material available for analysis (n=288) were studied for serum levels of miRNAs^[@R5]^. Patients received Velcade-Melphalan-Prednisone (VMP) or Velcade-Melphalan-Prednisone-Thalidomide followed by maintenance with Velcade-Thalidomide (VMPT-VT) through the parent clinical trial (NCT\#01063179).

RNA was isolated from the serum of 54 randomly selected MM patients, analyzed by NanoString, and only those miRNAs consistently expressed over the background threshold in at least 20% of samples were selected. These miRNAs were measured by qRT-PCR analyses using the 2\^-dct methods^[@R6],\ [@R7]^. In addition, a composite indicator of high risk genetic features was generated and evaluated in these analyses, where it was positive if the patient had any of the following: del17, t(4;14), t(14;16); otherwise, they were classified as standard risk.

Univariate Cox regression models were used to assess the influence of continuous expression levels for the miRNAs in relation to PFS and OS. We tested the proportional hazards assumption for a Cox regression model fit for each of the covariates^[@R8]^. In the presence of non-proportional hazards, weighted estimation in the Cox regression model was used to provide unbiased average hazard ratio estimates^[@R9]^. Any miRNA, clinical, and/or molecular covariates that were significant at the p\<0.10 level were brought forward for evaluation in the multivariable setting.

To identify circulating miRNAs with potential clinical impact, we analyzed by Nanostring the serum samples of a discovery set of 54 newly diagnosed MM patients randomly selected for analysis from 288 patients enrolled on a randomized phase III study of VMP versus VMPT-VT. ([Fig. A1, Supplementary Information Table A1](#SD1){ref-type="supplementary-material"}). Out of the 800 miRNAs evaluated, only 25 were detectable (≥100 counts) in at least 20% of the patients ([Figure. 1A,B](#F1){ref-type="fig"}). The expression of these miRNAs were then measured in a validation set of 234 patients by qRT-PCR. Of the 25 serum miRNAs (S-miRNAs), only 10 (S-miRs-92a, 21, 30a, 720, 451, 223, 126, 19b, 25 and S-miR-16) were validated to be differentially expressed among the patients in the validation set ([Supplementary Information Table A2](#SD1){ref-type="supplementary-material"}). These 10 miRNAs were not significantly associated with clinical or molecular characteristics at diagnosis ([Supplementary Information Table A3](#SD1){ref-type="supplementary-material"}). One exception was for chromosome 13q14 deletion (Del13), which was more frequently found in patients with low S-miR-16 (62% vs. 38%, p=0.003) and S-miR-19b (64% vs. 41%, p=0.01) level ([Supplementary Information Fig. A3](#SD1){ref-type="supplementary-material"}). In addition, some of the continuous miRNA levels were significantly correlated with age, hemoglobin and creatinine ([Supplementary Information Table A3](#SD1){ref-type="supplementary-material"}); however, these were weak associations (\|r\|\<0.22) and scatter-plots reflected weak if any relationships with these markers ([Supplementary Information Fig. A4](#SD1){ref-type="supplementary-material"}).

To assess prognostic impact, miRNA levels were evaluated as continuous variables. Of the 10 miRNAs, only S-miR-25 was significantly associated with both PFS (p=0.034) and OS (p=0.0005) in the univariate setting; S-miR-16 and S-miR30a were only associated with OS (p=0.008 and p=0.016 respectively). Patients with higher levels of S-miR*-*25 (HR 0.81; p=0.0005), S-miR-16 (HR 0.87; p=0.008), and S-miR-30a (HR 0.86, p=0.016) had longer OS than those with lower expression of these miRNAs ([Table 1](#T1){ref-type="table"}). Only S-miR-25 was significantly associated with PFS duration, where higher S-miR-25 expression was associated with better PFS duration (HR=0.92; p=0.034). A borderline significance for PFS and OS was also seen with S-miR-720, but was not statistically significant in multivariable models.

There was a statistically significant relationship between the presence of deletion 17 on FISH and both PFS (HR 2.12, p=0.005) and OS (HR 2.13, p=0.02). We noted that serum creatinine was highly significant for OS in the univariate setting (p=0.008). We converted serum creatinine levels to the more clinically meaningful estimated glomerular filtration rate (GFR) using the MDRD equation and thus adjusting for age, gender, and race. GFR was not significantly associated with OS (p=0.15). Of interest, univariate analyses for OS showed a strong gender effect (HR 1.8, p=0.014), where women had a survival advantage over men in this cohort. However, upon further evaluation, we uncovered that there was also a very significant relationship between gender and serum creatinine levels (p\<0.0001). This multicollinearity adds complexity to model building; despite this collinearity, both gender and serum creatinine were included in the multivariable model. Although not as "normalized" as the GFR measure we did not want to miss an effect of serum creatinine on OS in these patients.

To assess the independent prognostic impact of the miRNAs on PFS and OS duration, we evaluated several continuous serum miRNA markers in multivariable models that also adjusted for clinical and molecular factors of interest. When we evaluated S-miR-25 and S-miR-720 in relation to PFS when adjusting for the other identified significant factors (treatment arm, ISS stage, and del17), it was no longer significant for PFS (p=0.80). While not significant, S-miR-720 did maintain at least borderline significance for PFS (p=0.077).

In looking at OS, both S-miR-16 and S-miR-25 were each significantly associated with OS in the univariate setting. However, these two miRNA markers were also highly correlated (r = 0.75; p\<0.00001); therefore, we carried forward only S-miR-25 to the multivariable model since it had a greater observed effect and proved to provide a better fit in the models than when S-miR-16 was included. miR-*25* was also significantly correlated with miR-30a and miR-720 ([Table A5](#SD1){ref-type="supplementary-material"}), but these relationships were not as pronounced. To assess and identify a stable model, we evaluated the models with and without these correlated miRNA markers. Even when we included these additional miRNA markers in the model in addition to the clinical and molecular markers, S-miR-*25* retained its significance as a prognostic factor for OS whereas the others did not ([Table 1](#T1){ref-type="table"}).

Overall, multivariable models for PFS and OS showed that serum miRNA markers had a significant or at least borderline significant role in determining prognosis. This association was more pronounced when looking at OS, where S-miR-25 remained a significant and relevant factor (p=0.013) even when adjusting for Del17, Del13, ISS stage, treatment arm, and even creatinine and gender ([Table 1](#T1){ref-type="table"}). The multivariable model for PFS had fewer significant prognostic factors overall, although S-miR-720 still retained at least borderline significance (p=0.077) even when ISS stage and Del17 were included in the model ([Table 1](#T1){ref-type="table"}). The impact of S-miR-25 on OS can be readily seen when these levels are dichotomized as high vs. low (using a median cutpoint from S-miR-25 levels of healthy normals; HR=1.66, p=0.029, [Figure 1C](#F1){ref-type="fig"}).

In this analysis we found that gender and creatinine were both significant in the univariate setting. While the importance of gender has been rarely reported^[@R10]^, we discovered that creatinine and gender were collinear and MDRD, which depends on both gender and creatinine, was not an adequate composite variable. Creatinine is also a biomarker of more than renal function in this elderly population, varying by age, gender, weight, and often reflects muscle mass^[@R11]^.

Circulating miRNAs in MM are poorly understood. Their origin (cancer or normal cell), transit (actively secreted or derived at the time of apoptosis), and most influential location (within PBMCs, extracellular vesicles, or free floating) are all unknown. One report of circulating miRNA in MM identified let-7e and miR-744 as critical to differentiate from normal as well as correlate with overall survival, but this was based on a discovery set of just 13 patients^[@R12]^. A study of PBMCs from only 5 MM patients found numerous differences compared to 5 healthy controls^[@R13]^, but the small sample size limits generalizability.

We compared intracellular miR-16 and -25 expression in 32 paired samples of serum and PCs obtained patients with a new myeloma diagnosis, but there was no correlation, suggesting that circulating S-miR-16 and S-miR-25 do not reflect the miRNA content of myeloma cells in the marrow. By studying the biological significance of circulating miRNAs we found that miR-25 and miR-16 are encapsulated in extracellular vesicles but these miRNAs do not regulate their target genes post-transcriptionally, suggesting a different mechanism of regulation^[@R14]^. Additional work will be required to elucidate the mechanism of action of miR-25 and miR-16 in the extracellular compartment.

In conclusion, we show that circulating miR-16 and 25 are independent prognosticators in newly diagnosed MM of OS more so than PFS. We aim to validate these biomarkers in order to use them in combination with the ISS to better risk stratify MM patients.
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![(A) Supervised clustering analysis representative of the 800 miRNAs assessed using NanoString nCounter Technology and analyzed in 54 MM patients. Red cells indicate high expression and blue cells indicate low expression (B) list of the 25 miRNAs identified to be consistently expressed in at least 20% of MM samples analyzed. Overall survival (OS) for low vs. high expressors log~2~ S-miR-16 (C) and S-miR-25 (D) expression value were used to build OS curves. The median value of S-miR-16 and S-miR-25 for the healthy normal subjects was used as the cutoff expression value.](nihms588444f1){#F1}

###### 

Significant and shared characteristics from univariate analyses for PFS and OS

  Factor or Marker                                Progression-free survival (PFS)   Overall survival (OS)                                                                                      
  ----------------------------------------------- --------------------------------- ----------------------- ------- ------ ----------- ------- ------ ----------- -------- ------- ----------- -------
  VMPT (vs. VMP)[1](#TFN1){ref-type="table-fn"}   0.67                              0.49,0.92               0.013   \--    \--         \--     0.83   0.52,1.31   0.41     \--     \--         \--
  ISS stage[2](#TFN2){ref-type="table-fn"}        1.25                              0.99,1.58               0.06    1.41   1.05,1.89   0.022   1.42   1.02,1.98   0.039    1.34    0.82,2.18   0.24
  Creatinine                                      1.30                              0.92,1.83               0.14    \--    \--         \--     1.89   1.07,3.34   0.03     1.003   0.28,3.57   0.997
  Male (vs. female)                               1.03                              0.75,1.42               0.84    \--    \--         \--     1.80   1.13,2.88   0.014    2.29    1.05,4.98   0.037
  Del17[2](#TFN2){ref-type="table-fn"}            2.12                              1.25,3.59               0.005   2.29   1.17,4.50   0.016   2.13   1.13,4.03   0.02     1.30    0.51,3.30   0.59
  Del13                                           1.24                              0.87,1.77               0.23    \--    \--         \--     1.76   1.05,2.96   0.03     3.44    1.63,7.27   0.001
  miR-16[3](#TFN3){ref-type="table-fn"}           0.94                              0.88,1.02               0.13    \--    \--         \--     0.87   0.79,0.97   0.008    \--     \--         \--
  miR-25                                          0.92                              0.84,0.99               0.034   0.99   0.88,1.10   0.80    0.81   0.72,0.91   0.0005   0.76    0.62,0.94   0.013
  miR-30a[4](#TFN4){ref-type="table-fn"}          0.97                              0.90,1.05               0.49    \--    \--         \--     0.86   0.77,0.97   0.016    1.03    0.90,1.19   0.66
  miR-720[4](#TFN4){ref-type="table-fn"}          0.92                              0.85,1.01               0.077   0.89   0.79,1.01   0.077   0.87   0.76,1.01   0.06     0.91    0.77,1.07   0.26

In the multivariable analyses, the Cox regression models were stratified on treatment arm to accommodate any inherent differences in PFS or OS attributable to treatment arm

Failed assumptions of proportional hazards and adjusted for non-proportionality of hazards either by hypothesis test or by graphical interpretation of the Shoenfeld residuals

High positive correlation and issues of strong multicollinearity between miR-25 and miR-16 necessitated only including miR-25 in the model, which was the stronger of the two (r = 0.75, p\<0.000001)

Only failed proportional hazards assumption for OS, but not for PFS

ISS=International Staging System for multiple myeloma, ranging from 1 to 3; for this univariate model, ISS was treated as an ordinal variable. All serum miRs were log-transformed continuous measures. Hazard ratio \>1 indicates that those with this characteristic are at increased risk of the event; i.e. they tend to have shorter progression free survival (PFS) and overall survival (OS).

[^1]: These authors contributed equally to this work
